Florence Pasquier
Expertise in
15
conditions

Florence Pasquier

Queen Square, 
London, ENG, GB 
Expertise in
15
conditions
Queen Square, 
London, ENG, GB 

Overview

Florence Pasquier practices practicing medicine in London, United Kingdom.

Ms. Pasquier is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Dementia, Alzheimer's Disease, Frontotemporal Dementia, Vascular Dementia, and Thrombectomy.

She is actively involved in clinical research, co-authoring 337 peer reviewed articles and participating in 11 clinical trials.

Gender

Female

Locations

Queen Square, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke
Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke
Enrollment Status: Completed
Publish Date: December 16, 2025
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Enrollment Status: Completed
Publish Date: February 17, 2025
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 24, 2022
Intervention Type: Other
Study Phase: Not Applicable
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drugs: Flutemetamol, Florbetapir
Study Phase: Phase 3
MEMENTO-VAScular COmponents of Dementia
MEMENTO-VAScular COmponents of Dementia
Enrollment Status: Completed
Publish Date: January 28, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Patients With Alzheimer's Disease or Related Youth Disease
Patients With Alzheimer's Disease or Related Youth Disease
Enrollment Status: Completed
Publish Date: March 25, 2021
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
Enrollment Status: Terminated
Publish Date: March 31, 2020
View 9 Less Clinical Trials

336 Total Publications

Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology.
Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology.
Journal: Cell press blue
Published: May 25, 2026

Frequently Asked Questions about Florence Pasquier

Is Florence Pasquier a top-rated expert for Dementia?

MediFind is an objective health platform that identifies experts based on real-world data. Florence Pasquier is classified as an Distinguished expert for Dementia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Florence Pasquier participate in research or clinical trials?

Yes. Florence Pasquier has published 336 articles and abstracts on conditions like Dementia. You can view a list of Florence Pasquier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pasquier's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile